24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Alphabet, Amazon.com, General Electric, Gilead Sciences, Intel, Seagate Technology and U.S. Steel.
Monday was a down day for the U.S. markets. Although the markets have been pushing new highs recently, today was not one of those days. Crude oil started the week out on…
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
The top analyst upgrades, downgrades and other research calls from Friday include Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead Sciences, Intel, Starbucks and Yamana Gold.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that…
The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences, Micron Thecnology, NVIDIA, Procter & Gamble and Qualcomm.
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Wednesday include Alcoa, Extreme Networks, Gilead Sciences, MGIC, Micron, Noble Energy, Twitter, U.S. Steel and Wendy's
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
